Haleon HLN
NYSE HLN
$9.85 -0.02 (-0.15%)
At close: Aug 20, 2026 · 10:03 AM UTC

Haleon (HLN) Net Income towards Common Stockholders (2021 - 2025)

Haleon's (HLN) quarterly Net Income towards Common Stockholders came in at $1.1 billion in Q4 2025, up 26.65% on a QoQ basis from $852.7 million in Q4 2023.

Haleon (HLN) Net Income towards Common Stockholders (2021 - 2025) Analysis & Trends

Haleon (HLN) has 4 years of Net Income towards Common Stockholders data on file, last reported at $1.1 billion in Q4 2025.

  • Quarterly Net Income towards Common Stockholders changed N/A year-over-year to $1.1 billion in Q4 2025, while the trailing twelve-month figure through Jun 2026 was $1.1 billion (changed N/A YoY) and the FY2025 annual result came in at $2.2 billion, up 20.3% from the prior year.
  • Net Income towards Common Stockholders improved to $1.1 billion in Q4 2025, from $852.7 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $1.2 billion in Q4 2021 to a low of $372.9 million in Q2 2023.
  • A 4-year average of $798.7 million and a median of $852.7 million in 2023 frame the typical range for Net Income towards Common Stockholders.
  • Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders fell 12.99% — and 2023, when it dropped 15.67%.
  • Tracing HLN's Net Income towards Common Stockholders over 4 years: stood at $1.2 billion in 2021, then retreated by 12.99% to $1.0 billion in 2022, then slipped by 15.67% to $852.7 million in 2023, then rose by 26.65% to $1.1 billion in 2025.
  • The last three Net Income towards Common Stockholders figures came in at $1.1 billion (Q4 2025), $852.7 million (Q4 2023), and $372.9 million (Q2 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Haleon 43.76 Bn 42.80 Bn - -
2 Teva Pharmaceutical Industries 43.05 Bn 39.39 Bn 2.15 Bn -576.00 Mn
3 Zoetis 31.51 Bn 29.84 Bn 1.05 Bn 866.00 Mn
4 Takeda Pharmaceutical 28.70 Bn 22.90 Bn 5.10 Bn 710.19 Mn
5 United Therapeutics 22.27 Bn 19.61 Bn 683.80 Mn 333.00 Mn
6 Viatris 18.83 Bn 17.95 Bn 1.46 Bn -118.80 Mn
7 Neurocrine Biosciences 15.65 Bn 15.26 Bn 935.80 Mn 144.40 Mn
8 Elanco Animal Health 12.06 Bn 11.53 Bn 798.00 Mn 54.00 Mn
9 Dr Reddys Laboratories 10.12 Bn 9.95 Bn - -
10 Alkermes 8.27 Bn 7.61 Bn 397.90 Mn 524,000.00

Historic Data

Download Data
DateValue
Dec 31, 2025 1.08 Bn
Dec 31, 2023 852.67 Mn
Jun 30, 2023 372.91 Mn
May 3, 2023 475.66 Mn
Dec 31, 2022 1.01 Bn
Sep 20, 2022 636.58 Mn
Dec 31, 2021 1.16 Bn